Raltegravir Pharmacokinetics and Safety in Neonates
Phase of Trial: Phase IV
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms IMPAACT-P1097
- 31 Aug 2018 Biomarkers information updated
- 23 Jul 2018 Status changed from active, no longer recruiting to completed.
- 29 May 2018 Planned primary completion date changed from 1 Dec 2018 to 31 Aug 2018.